SKISTAR’S IMPROVED FULL-YEAR RESULTS ENABLE CONTINUED DEVELOPMENT OF MOUNTAIN DESTINATIONS FOR THE FUTURE

Fourth Quarter

  • Net sales amounted to SEK 292 million (226), an increase of SEK 66 million, 29 percent.
  • Operating profit amounted to SEK -274 million (-310), an increase of SEK 36 million, 12 percent.
  • Operating profit adjusted for capital gains from exploitation assets amounted to SEK -276 million (-310), an increase of SEK 34 million, 11 percent.
  • Capital gains from exploitation assets were included with SEK 2 million (0).
  • Cash flow from operating activities amounted to SEK -176 million (-161), a decrease of SEK 15 million.
  • Basic and diluted earnings per share amounted to SEK -2.87 (-3.35), an increase of 14 percent.

Full Year

  • Net sales amounted to SEK 4,954 million (4,574), an increase of SEK 380 million, 8 percent.
  • Operating profit amounted to SEK 872 million (785), an increase of SEK 87 million, 11 percent.
  • Operating profit, adjusted for capital gains from exploitation assets, amounted to SEK 870 million (739), an increase of SEK 131 million, 18 percent.
  • Capital gains from exploitation assets were included with SEK 3 million (46).
  • Cash flow from operating activities amounted to SEK 1,223 million (1,063), an increase of SEK 160 million.
  • Basic and diluted earnings per share amounted to SEK 8.01 (7.05), an increase of 14 percent.

Significant events during and after the period

  • The Board proposes a dividend of SEK 3.50 (3.00) per share, totaling SEK 274 (235) million. The dividend represents 44 percent (43) of the Group’s profit after tax.
  • Booking volumes for the winter season 2026/27, measured as the number of overnight stays booked through SkiStar’s mediated accommodation, are up 3 percent compared with the same time of the previous year.

Comments from the CEO Stefan Sjöstrand:

“The strong full-year results mean that SkiStar is well equipped for continued growth and long-term value creation, with the ambition to be a leading force in mountain tourism, and to continue offering mountain experiences for many generations to come.”

Time for conference call and web presentation

Wednesday 30 September 2026 at 10.00 a.m. CEST.
Web cast: https://edge.media-server.com/mmc/p/ukztm9re

Web cast & participation at conference call to ask questions:
https://register-conf.media-server.com/register/BI443fdd8b16b7404eb960396af94b6272

For registration and dial-in details, please follow the link above. Please make sure you are connected to the phone conference by calling in and registering a few minutes before the conference begins.

The presentation and a recorded version of the web presentation will be available on the same webpage after the presentation.

This information is information that SkiStar AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact persons set out below, on 30 September 2026, at 07.00 a.m. CEST.

Further information can be reached from:

Stefan Sjöstrand, CEO, tel +46 (0)280 841 60.
Sara J Uggelberg, CFO, tel +46 (0)280 841 60.

SkiStar in brief

SkiStar AB (publ) is the leading mountain tourism group in Scandinavia, developing destinations and experiences focused on guests. The Company’s B share is listed on the Large Cap list of the Nasdaq Stockholm exchange. The Group owns and operates mountain resorts in Sälen, Vemdalen, Åre and Stockholm (Hammarbybacken) in Sweden, and in Hemsedal and Trysil in Norway. Operations are divided into two segments: Mountain Resorts and SkiStarshop. With alpine skiing as its core activity, SkiStar’s ambition is to be a leading force in mountain tourism, and to continue offering mountain experiences for many generations to come. For more information, go to https://investor.skistar.com/en.

Attachment

  • Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in delaying disability1
  • Fenebrutinib became the first investigational medicine in more than a decade to slow disability progression in a Phase III PPMS trial (FENtrepid), with numerical benefit vs Ocrevus2
  • Fenebrutinib is designed to address two drivers of MS – acute inflammation causing relapses and chronic brain inflammation driving disability progression1,2
  • If approved, fenebrutinib would become the first BTK inhibitor and first high-efficacy oral treatment for both RMS and PPMS, offering a new option for the nearly 1 million Americans living with MS3

Basel, 30 September 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) under priority review for fenebrutinib, an investigational non-covalent Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The filing acceptance is based on data from the comprehensive clinical programme, including the Phase III FENhance 1 and 2 RMS studies and the Phase III FENtrepid PPMS study.1,2

“People living with multiple sclerosis need treatments that go beyond controlling relapses to help preserve function and independence as the disease progresses,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Three Phase III studies have demonstrated the potential for fenebrutinib to address both relapsing and progressive disease, thereby bringing us closer to an oral treatment that could make a meaningful difference across the MS spectrum.”

“Ocrevus transformed how we treat MS, helping more than 525,000 people live a life less defined by their disease. Yet, over a third of all people with MS still receive lower-efficacy treatment,” said Teresa Graham, Roche’s Chief Executive Officer, Pharma. “If approved, fenebrutinib could open a new chapter as the first high-efficacy oral therapy for both relapsing and primary progressive MS, helping to control disease activity while giving people more flexibility and choice.”

Concurrently addressing the life-disrupting relapses and long-term disease progression – the slow, steady loss of physical and mental abilities over time – remains one of the greatest challenges in MS.4 Fenebrutinib is designed to act throughout the body and to cross the blood-brain barrier into the central nervous system to target both the acute inflammation that causes relapses and the chronic inflammation that is thought to drive disability progression.1,2

The NDA for fenebrutinib is supported by three positive Phase III studies:

  • The FENhance 1 and 2 RMS studies showed that fenebrutinib significantly reduced relapses and both active and chronic brain lesions compared with standard of care, teriflunomide. Fenebrutinib reduced the annualised relapse rate (ARR) by 51.1% (p<0.001) in FENhance 1 and 58.5% (p<0.00001) in FENhance 2 compared with teriflunomide over 96 weeks. This equates to patients having approximately one relapse every 17 years, which is the lowest relapse rate seen in Phase III MS studies. In addition, measures of disability progression, including 12-week composite confirmed disability progression (cCDP12), showed consistent positive trends favouring fenebrutinib over teriflunomide.1
  • The FENtrepid PPMS study showed fenebrutinib met its primary endpoint of non-inferiority compared with Ocrevus® (ocrelizumab), the current standard of care and only approved medicine for PPMS, in reducing disability progression. Fenebrutinib numerically reduced the risk of progression by 12% compared to Ocrevus, as measured by the time to onset of cCDP12 (hazard ratio [HR] 0.88; 95% confidence interval [CI]: 0.75, 1.03), with curves separating as early as 24 weeks. A consistent treatment effect on disability progression was observed across patient subgroups, including those without active inflammation, and for the entire treatment duration after 24 weeks.2

The overall rate of serious adverse events for fenebrutinib and teriflunomide, respectively, was 9% and 9% in FENhance 1 and 11% and 6% in FENhance 2. The overall rate of serious adverse events in FENtrepid was 19% for fenebrutinib and 19% for Ocrevus. Liver enzyme elevations were comparable between the fenebrutinib and teriflunomide arms in the RMS studies and observed more often with fenebrutinib compared to Ocrevus in the PPMS study. While an imbalance in reported fatalities was observed across the three pivotal studies, the deaths occurred at different timepoints and had various causes.1,2 Overall, fenebrutinib has shown a manageable safety profile across the three Phase III trials and earlier studies, with a large safety database including more than 2,700 study participants.1,2,5

About fenebrutinib
Fenebrutinib is an investigational oral, central nervous system (CNS)-penetrant, reversible and non-covalent Bruton’s tyrosine kinase (BTK) inhibitor with an optimised pharmacokinetics (PK) profile. Fenebrutinib can act throughout the body and also cross the blood-brain barrier into the CNS to target chronic inflammation. It is uniquely designed to target relapsing and progressive biology by inhibiting cells in the immune system known as B cells and microglia. Targeting B cells helps control the acute inflammation that causes relapses, while targeting microglia inside the brain addresses the chronic damage that is thought to drive long-term disability progression.

While most current BTK inhibitors are covalent and irreversible, meaning they form a permanent chemical bond with the enzyme, fenebrutinib is non-covalent and reversible, meaning it binds and then eventually releases the enzyme.

About multiple sclerosis
Multiple sclerosis is a chronic disease that affects more than 3 million people worldwide. People with all forms of multiple sclerosis experience disease progression from the beginning of their disease. Therefore, an important goal of treating multiple sclerosis is to slow, stop and ideally prevent progression as early as possible.

Approximately 85% of people with multiple sclerosis are initially diagnosed with relapsing-remitting multiple sclerosis (RRMS). Relapsing forms of the disease (RMS) include RRMS and active secondary progressive MS, and people with RMS experience relapses and worsening disability over time. Primary progressive multiple sclerosis (PPMS) is a debilitating form of the disease marked by steadily worsening symptoms but typically without distinct relapses or periods of remission. Approximately 15% of people with multiple sclerosis are diagnosed with the primary progressive form of the disease. Until the FDA approval of Ocrevus®, there had been no FDA-approved treatments for PPMS, and Ocrevus is still the only approved treatment for PPMS.

About Roche in Neurology
Neurology is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new diagnostics and treatments that help improve the lives of people with chronic and potentially devastating diseases globally.

Roche is investigating more than a dozen medicines for neurological conditions, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and Duchenne muscular dystrophy. Roche Diagnostics has developed a broad range of approved and investigational tools, including digital and blood-based tests and cerebrospinal fluid (CSF) assays, aiming to more effectively detect, diagnose and monitor neurological conditions. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neurology today.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.
Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Oh J, et al. Efficacy and Safety of Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results of the FENhance 1 and 2 Studies. Presented at: 2026 American Academy of Neurology (AAN) Annual Meeting; April 21, 2026; Chicago, IL, USA, and virtual.
[2] Bar-Or A, et al. Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study. Presented at: Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2026; February 7, 2026; San Diego, CA, USA, and virtual.
[3] MS International Federation. Atlas of MS. [Internet; cited September 2026]. Available from: https://atlasofms.org/map/global/epidemiology/number-of-people-with-ms 
[4] Bittner S, Zipp F. Progression in multiple sclerosis – a long-term problem. Curr Opin Neurol. 2022;35(3):293-298. doi:10.1097/WCO.0000000000001044
[5] Bar-Or A, Dufek M, Budincevic H, et al. Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study. Lancet Neurol. 2025;24(8):656-666. doi:10.1016/S1474-4422(25)00174-7

Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com

Tristan Schmitz
Phone: +41 79 529 70 35
Lorena Corfas
Phone: +41 79 568 24 95
Simon Goldsborough
Phone: +44 797 32 72 915
Karsten Kleine
Phone: +41 79 461 86 83
Kirti Pandey
Phone: +41 79 398 38 53
Yvette Petillon
Phone: +41 79 961 92 50
Irène Stephan
Phone:  +41 79 377 83 75
Albert Thottiyil
Phone: +41 79 775 66 12

Roche Investor Relations

Dr Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
 

Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
 

Attachment

Ad hoc announcement pursuant to Art. 53 LR.

A conference call will be held on September 30, 2026, at 14:00 CEST / 13:00 BST / 08:00 EDT.
Details are at the end of this news release

Strong momentum and expanding global access position AGAMREE® for continued growth

Pratteln, Switzerland, September 30, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces the Company’s financial results for the six months ended June 30, 2026.

Orlando Oliveira, CEO of Santhera said: “We made strong progress in the first half of 2026, with growing commercial momentum for AGAMREE® and significant advances in patient access globally. In Europe, pricing and reimbursement agreements in Spain and Italy mean that AGAMREE® is now commercially available in four of the five major EU markets, while our agreement with Nxera significantly expands our reach across key APAC territories. Importantly, the long-term data presented in March further reinforced AGAMREE®’s differentiated profile in DMD and has supported increased physician adoption. With our partners also continuing to rapidly expand access across their territories, AGAMREE® is reaching a growing number of patients worldwide, positioning us well to build on this momentum through the remainder of 2026 and beyond.”

Operational Highlights (Including post period events)

  • Four of five major EU markets now commercially launched: Pricing and reimbursement agreements were secured in Spain and Italy during the first half of 2026, adding to continued strong commercial momentum in Germany and the UK.
  • Strategic APAC licensing agreement signed with Nxera: Exclusive licensing agreement for Japan, South Korea, Australia and New Zealand valued at up to USD 215 million plus royalties, including USD 30 million in cash and a USD 10 million equity investment in Santhera.
  • Continued progress across mid-sized direct European markets: Swissmedic approved AGAMREE® in Switzerland in January 2026, while pricing and reimbursement was agreed in Luxembourg in August, marking the first Benelux market to secure reimbursement.
  • Distributor markets continue to expand: Santhera expanded its agreement with Biomedica to include Georgia, Kazakhstan, Belarus, Azerbaijan and Uzbekistan, while Genesis secured marketing authorization for AGAMREE® in Serbia in September, further expanding patient access across its territories.
  • Long-term data further reinforce AGAMREE®’s differentiated profile: Data from up to eight years of AGAMREE® treatment, including baseline results from the ongoing Phase 4 GUARDIAN study, were presented at MDA in March 2026, demonstrating comparable long-term effectiveness to standard-of-care corticosteroids alongside clinically meaningful safety advantages.
  • Additional data and label expansion support continued growth and positioning: CHMP adopted a positive opinion recommending extension of AGAMREE®’s EU authorization to patients from two years of age, while emerging real-world experience from a case series in adult, non-ambulatory DMD patients presented at ICNMD showed stabilization or improvement in upper-limb function in this patient population.
  • Executive and Board Changes: Orlando Oliveira was appointed CEO in July, Marc Clausse joined as Chief Commercial Officer in June, and Dr. Srishti Gupta was elected to Santhera’s Board in May.

Financial Highlights

  • Total revenue increased 101% to CHF 48.3 million (H1 2025: CHF 24.0 million), driven by strong growth in product sales and income recognized from the Nxera licensing agreement.
  • Product sales increased 48% to CHF 17.2 million (H1 2025: CHF 11.6 million), reflecting continued strong growth across Santhera’s launched markets.
  • Royalties and milestones increased to CHF 29.1 million (H1 2025: CHF 6.5 million), primarily driven by the USD 30 million (CHF 24.2 million) cash upfront payment received under the Nxera licensing agreement.
  • Revenue from the supply of products and services to partners decreased, as expected, to CHF 2.1 million (H1 2025: CHF 5.9 million), primarily reflecting Catalyst’s transition to direct sourcing.
  • Global AGAMREE® sales, including partner sales, exceeded USD 175 million on a four-consecutive-quarter basis in Q2 2026, triggering a USD 20 million (CHF 16.3 million) sales milestone payment obligation, recognized in cost of sales.
  • Operating expenses decreased 8.4% to CHF 25.0 million (H1 2025: CHF 27.3 million), primarily due to lower development costs.
  • Operating loss narrowed significantly to CHF 6.6 million (H1 2025: CHF 35.4 million).
  • Cash and cash equivalents increased to CHF 41.8 million at June 30, 2026, compared with CHF 22.4 million at December 31, 2025.
  • Full-year 2026 guidance maintained, with total revenue expected to be in the range of CHF 80–90 million.
  • Cash and cash equivalents: While cash is expected to remain broadly stable at 30 September levels through the end of the year, the movement of inventory purchases into Q1 2027, combined with a mandatory German price reduction effective from Q1 2027, is expected to result in a decline in cash during H1 2027, before the Company returns to cash generation in the second half of the year. This change in the cash profile, however, will not require the Company to seek any additional funding.

Half Year Report
The Santhera Half Year Report 2026 (English only) is available for download on the Company’s website at www.santhera.com/financial-reports.

Analyst Briefing
Santhera’s management team will be hosting a briefing for analysts and investors via a webcast at 14:00 CEST (08:00 EDT) on 30 September 2026.

Register here: https://www.investormeetcompany.com/santhera-pharmaceuticals-holding-ag/register-investor

A recording of the webcast and the results presentation will be made available on the website following the event.

About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE® (vamorolone), a dissociative corticosteroid with a novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE® for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Commission (EC), in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), in Switzerland by Swissmedic, in China by the National Medical Products Administration (NMPA), in Hong Kong by the Department of Health (DoH) and in Canada by Health Canada. Santhera has out-licensed the rights to AGAMREE® as follows: to Catalyst Pharmaceuticals for North America; to Sperogenix Therapeutics for China and certain countries in Southeast Asia; and to Nxera Pharma for Japan, South Korea, Australia, and New Zealand. For further information, please visit www.santhera.com.

AGAMREE® is a trademark of Santhera Pharmaceuticals.

For further information, please contact:

Santhera
Catherine Isted, Chief Financial Officer:   IR@santhera.com

ICR Healthcare:  Santhera@icrhealthcare.com

Stifel  +44 (0)20 7710 7600
Brough Ransom, Charles Hoare, Fred Walsh

Octavian +41 (0)44 520 1588
Serge Monnerat, Marius Zuberbuehler

Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

# # #

Business Review

Introduction
Santhera continued to make strong progress in the first half of 2026, driven by the expanding commercial rollout of AGAMREE® and increasing patient access across both direct and partner markets. Commercial momentum remained strong in Germany and the UK, while pricing and reimbursement agreements in Spain and Italy expanded availability to four of the five major European markets. Beyond Santhera’s direct territories, the Nxera licensing agreement significantly extended AGAMREE®’s commercial reach in APAC, while partners continued to advance access across the US, China and distributor markets. This commercial progress was complemented by new long-term and real-world data further supporting AGAMREE®’s differentiated profile and its potential across a broader DMD patient population.

Advancing the rollout of AGAMREE® in Santhera’s Major EU Direct markets

Commercial uptake of AGAMREE® continued to build across Santhera’s established European markets during the first half of 2026. In Germany, Santhera’s largest market, demand remained strong, with volumes in H1 2026 increasing by more than 50% compared with H1 2025. While the price per bottle decreased to EUR 3,001 in January 2026 from EUR 3,612, reflecting a one-time, pre-agreed price adjustment at the time of initial pricing and reimbursement in early 2025, strong volume growth has more than offset this impact.

In the UK, following launch in Q2 2025, uptake continued to progress, supported by increasing systematic adoption across specialist DMD centres and benefitting from updated treatment guidelines and improved access initiatives, including home delivery programs. The publication of the long-term data in March 2026, combined with the access initiatives described above, contributed to orders increasing by more than 40% in Q2 2026 compared with the previous quarter.

Significant progress was also made in two of Santhera’s largest remaining direct European markets, Spain and Italy, with pricing and reimbursement agreed in both countries during the first half of the year. In Spain, AGAMREE® has been available through a named-patient program since mid-2024. In February 2026, AGAMREE® was proposed for inclusion in Spain’s National Health System, and the launch commenced in Q2. As part of the agreement with the Spanish National Health System and to accelerate patient access to therapy, Santhera provided product free of charge during Q2, with the full commercial sales commencing in July.

In Italy, following submission of the long-term data, pricing and reimbursement was agreed in late Q2, with first commercial sales also in July.

With AGAMREE® now commercially available in four of the five major EU markets, attention is increasingly focused on France. As previously indicated, the French reimbursement process is expected to take longer and will require a full resubmission, this will however benefit from the new positive data that has become available. A commercial launch is therefore not currently expected before 2028, although Santhera is exploring potential routes to accelerate access for French patients.

Continued progress in other mid-sized direct EU markets

Santhera made further progress on regulatory and reimbursement milestones across its direct European markets during the period. In January 2026, Swissmedic approved AGAMREE® for the treatment of DMD in patients aged 4 and older, and post period in August 2026, pricing and reimbursement was agreed in Luxembourg, marking the first Benelux approval.

Santhera continues to engage with pricing and reimbursement authorities across the other Benelux countries, the Nordics, Portugal, Switzerland and Ireland. Santhera remains focused on achieving pricing that appropriately reflects AGAMREE®’s value and is consistent with established major European markets. The Company is also evaluating alternative access pathways where available.

Distributor Market – Strong momentum across multiple markets
Since July 2024, Santhera has worked closely with Genesis Pharma to advance the phased rollout of AGAMREE® across Central and Eastern European markets where Santhera does not sell directly. In September, they secured Marketing Authorization in Serbia, representing a key milestone in the continued expansion of AGAMREE® access beyond the EU. Through Genesis Pharma AGAMREE® is to date available through various market access pathways in Greece, Cyprus, Malta, the Czech Republic, Poland, Romania, Hungary, Bulgaria, Slovenia, Croatia, Lithuania, and Estonia, with the team looking to expand this further.

Commercial momentum across Santhera’s distributor markets continued to strengthen during the period, with Genesis and Megapharm delivering strong sales growth alongside increasing contributions from other distribution partners. In July 2026, Santhera further expanded its distribution agreement with Biomedica to include Georgia, Kazakhstan, Belarus, Azerbaijan and Uzbekistan, extending potential access to AGAMREE® to an estimated 2,000 additional DMD patients across Central Asia and the Caucasus.

Strategic APAC partnership with Nxera
In January 2026, Santhera entered into an exclusive licensing agreement with Nxera Pharma for the development, manufacturing and commercialization of AGAMREE® in Japan, South Korea, Australia and New Zealand. The agreement is valued at up to USD 215 million plus royalties and included a USD 40 million upfront payment, comprising USD 30 million in cash and a USD 10 million equity investment in Santhera at a 20% premium to the 30-day VWAP prior to the day of announcement. Santhera is also eligible to receive double-digit tiered royalties on net sales in the licensed territories.

The partnership significantly expands AGAMREE®’s commercial reach across the APAC region. In June 2026, AGAMREE® was granted ODD and GIFT designations by South Korea’s Ministry of Food and Drug Safety, supporting an accelerated regulatory pathway in the country.

Separately, Nxera has indicated it plans to file for regulatory approval for AGAMREE® in Japan in the second half of 2027 and to extend AGAMREE® into three additional rare disease indications, including Fukuyama congenital muscular dystrophy, pediatric nephrotic syndrome and juvenile dermatomyositis.

Continued strong momentum with US partner Catalyst, now part of Angelini Pharma
AGAMREE® continued to deliver strong commercial growth in the US during the first half of 2026. Santhera’s US partner Catalyst Pharmaceuticals reported AGAMREE® net product revenue of USD 36.7 million in Q1 2026, compared with USD 22.0 million in Q1 2025. Prior to its acquisition by Angelini Pharma, Catalyst had guided to FY 2026 AGAMREE® net product revenue of USD 140–150 million and reported that 90% of DMD Centers of Excellence had started using AGAMREE® for their patients.

In May 2026, Angelini Pharma S.p.A. announced an agreement to acquire Catalyst for approximately USD 4.1 billion, with the transaction completing on July 16, 2026. The acquisition established Angelini Pharma’s presence in rare diseases and created a commercial presence in the US.

In June 2026, Catalyst also reported results from a Phase 1 clinical study suggesting that AGAMREE® delivers glucocorticoid and anti-inflammatory activity while avoiding significant immunosuppressive effects at approved dosing, supporting its potential evaluation across a broader range of chronic inflammatory rare diseases.

Since mid-2025, Catalyst has held the license to manufacture AGAMREE® for North America and has established its own drug product manufacturing capabilities to serve the territory. Following the transition to direct sourcing, Santhera does not expect to generate further product sales to its North American partner from Q1 2026 onwards, while continuing to benefit from royalties, potential milestone and service related payments under the licensing agreement.

Sperogenix advancing AGAMREE® access in China
In China, Santhera’s partner Sperogenix continued its non-reimbursed commercial rollout of AGAMREE®, following its launch in September 2025. Patient numbers continue to grow, with more than 1000 patients treated to date. Product sales to Sperogenix are expected to be significantly higher in the second half of the year, following the shipment of a larger number of batches in Q3.

China represents a significant long-term growth opportunity, with ongoing efforts focused on expanding access, preparing for potential inclusion in national reimbursement frameworks, and discussing technology transfer to potentially enable local manufacturing from 2028.

Continued positive data on AGAMREE® drives sales growth and label extension
In March 2026, Santhera presented long-term real-world comparative analyses, including baseline data from the ongoing Phase 4 GUARDIAN study, at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Orlando, Florida. The dataset included up to eight years of AGAMREE® exposure, with a median treatment duration of approximately five years, compared with a propensity-matched historical cohort treated with deflazacort or prednisone.

The analyses demonstrated comparable long-term effectiveness to classic corticosteroids based on time to loss of ambulation, alongside a markedly improved safety profile, including significantly fewer vertebral fractures and cataracts, and maintenance of normal growth. No new safety signals were identified. The prospective GUARDIAN study will continue to generate additional long-term data over the coming years.

Additionally at the International Congress on Neuromuscular Diseases (ICNMD) in July 2026, investigators from centres in Munich, Germany and Vienna, Austria presented in a case series, the first real-world experience of AGAMREE® in adults with DMD. The retrospective analysis covered 25 adult patients, with a median age of 23 years, all of whom had been non-ambulatory for a median of more than ten years prior to starting treatment. Nineteen patients had previously received a corticosteroid, including 11 who had discontinued treatment before starting on AGAMREE®; the remaining six patients were corticosteroid-naïve.

In the subset of thirteen patients assessed for upper-limb function, eight showed stabilization or improvement. In addition, patients with pre-existing corticosteroid-related side effects, including obesity and Cushingoid features, showed reduced or resolved symptoms on AGAMREE®, with no new safety signals reported at last follow-up. These findings support current guideline recommendations on the potential role of continued corticosteroid treatment beyond loss of ambulation and highlight opportunities for further evidence generation in adult DMD.

In April 2026, the CHMP adopted a positive opinion recommending extension of AGAMREE®’s EU marketing authorization to include patients from 2 years of age.

Executive and Board changes
Santhera continued to evolve its leadership and governance during the period. In April 2026, the Company announced a planned CEO transition, with Orlando Oliveira appointed as Chief Executive Officer effective July 15, 2026, succeeding Dario Eklund. In March 2026, the Company announced the appointment of Marc Clausse as Chief Commercial Officer, effective June 1, 2026, succeeding Geert Jan van Daal, who retired after 11 years with the Company.

Dr. Srishti Gupta was elected to the Board at the Annual General Meeting on May 26, 2026, where shareholders approved all Board proposals, including the re-election of Thomas Meier as Chairman.

Financial Guidance and Outlook
Revenue guidance remains unchanged, with total revenue expected to be in the range of CHF 80–90 million. Within this, product sales are expected to grow by more than 50%, while royalty income from Catalyst and Sperogenix is expected to increase year-on-year. However, royalty income from Catalyst will lag underlying US sales growth due to a step-down in the royalty rate applicable to the first USD 100 million of US sales following the initial 24-month post-launch period.

Milestone income is expected to exceed 2025 levels, driven primarily by the USD 30 million upfront payment from Nxera. Additional sales milestones may be achieved during 2026; however, these are not currently included in revenue guidance, pending greater visibility on the commercial performance of licensing partners during the second half of the year.

Revenue from product supply and services is expected to decline significantly compared with 2025. Increased supply volumes to China will not fully offset the reduction in US product sales following Catalyst’s transition to direct sourcing from Q1 2026. However, revenue from product supply and services is expected to be significantly higher in the second half than in the first half of the year, following a sizeable number of shipments to Sperogenix in Q3.

Operating expenses are expected to remain within the previously guided range of CHF 50–55 million.

Following the commercial launches in Spain and Italy in July 2026, a one-off USD 20 million non-sales-related milestone linked to the third commercial launch in a major European market became payable to ReveraGen and R-Bridge, which had previously assumed the former Idorsia milestone rights. The milestone has been recorded within cost of sales (COS). Approximately 75% of the payment was made in Q3, with the remainder to be paid in line with corresponding cash inflows.

Cash is expected to remain broadly stable at 30 September levels through the end of the year. The movement of inventory purchases into Q1 2027, combined with a new mandatory government-imposed pricing discount in Germany effective from Q1 2027, is expected to result in a decline in cash during H1 2027, before the Company returns to cash generation in the second half of the year. This change in the cash profile, however, will not require the Company to seek additional funding.

Santhera reiterates its mid-term outlook for total revenue, excluding milestones, of approximately CHF 140 million (previously communicated as EUR 150 million) in 2028 and extends this outlook to 2030, targeting approximately CHF 250 million.

Financial Review

Net Revenue
In the first half of 2026, Santhera reported revenue from contracts with customers of CHF 48.3 million (H1 2025: CHF 24.0 million) driven by continued sales growth in launched markets and the upfront milestone received under the exclusive license and collaboration agreement signed with Nxera Pharma UK Ltd. for AGAMREE® in Japan, South Korea, Australia and New Zealand. Product sales amounted to CHF 17.2 million following the continued success of AGAMREE® in large markets such as Germany and the UK (H1 2025: CHF 11.6 million). Royalties and net sales to licensing partners decreased to CHF 4.8 million and CHF 2.0 million (H1 2025: CHF 5.4 million and CHF 5.7 million), driven primarily by Catalyst’s transition to direct sourcing as well as a decrease in royalty rates per the contract. Milestone income increased to CHF 24.3 million during the period, compared with CHF 0.9 million in H1 2025, following the closing of the exclusive license and collaboration agreement with Nxera Pharma UK Ltd.

Cost of sales
Cost of sales decreased to CHF 30.0 million (H1 2025: CHF 32.1 million). The decrease was driven by a decrease in milestone expense recognized during the period. During the first half of 2026, the Company recognized a sales milestone payment obligation to ReveraGen of USD 20 million (CHF 16.3 million) for global sales reaching in excess of USD 175 million on a four consecutive quarters basis. This compared to USD 25 million (CHF 20.3 million) in the prior-year period. As with previous sales milestones, while the milestone is recognized at the time it is achieved, it has been agreed that it will be paid in line with cashflow generation. Cost of sales for the six months also included non-cash intangible amortization of CHF 2.5 million (H1 2025: CHF 2.5 million) and royalties payable of CHF 5.4 million (H1 2025: CHF 3.7 million).

Operating expenses and result
Operating expenses of CHF 25.0 million (H1 2025: CHF 27.3 million) decreased from the prior year driven by the continued overall decrease in development expenses as the product moves further into the commercialization process.

Development expenses amounted to CHF 9.9 million (H1 2025: CHF 11.7 million). The decrease of -15% was driven by the completion of longer-term studies and certain CMC (chemistry, manufacturing, and controls) development activities coming to a close in the prior year.

Marketing and sales expenses were CHF 6.2 million (H1 2025: CHF 6.8 million), while general and administrative expenses amounted to CHF 8.9 million (H1 2025: CHF 8.8 million). Both remaining largely consistent to support the commercialization of AGAMREE®.

The operating result amounted to a CHF -6.6 million loss (H1 2025: CHF -35.4 million loss).

Financial income and expenses
Financial income amounted to CHF 6.3 million (H1 2025: CHF 8.1 million). The decrease was predominantly related to a lower gain in the fair value of financial instruments.

Financial expenses were CHF 21.2 million (H1 2025: CHF 11.4 million), primarily due to higher interest expenses as well as an increase in the change in fair value of derivatives.

Overall, this resulted in a net financial expense of CHF -14.9 million, compared with CHF -3.3 million in H1 2025.

Net result
The net result in H1 2026 was a loss of CHF -21.5 million, compared to a loss of CHF -38.8 million in H1 2025. The improvement was mainly driven by the upfront payment received upon signing the exclusive license and collaboration agreement with Nxera for AGAMREE® in Japan, South Korea, Australia and New Zealand, partially offset by the one-time USD 20 million (CHF 16.3 million) milestone payable and higher financial expenses.

Cash balance and cash flows
As of June 30, 2026, the Company had cash and cash equivalents of CHF 41.8 million compared with CHF 22.4 million as of December 31, 2025. This represents an increase of CHF 19.4 million (H1 2025: decrease of CHF -22.5 million).

Net cash flow from operating activities amounted to CHF 14.8 million (H1 2025: net cash outflow of CHF -20.6 million).

Net cash flow from financing activities amounted to CHF 4.1 million (H1 2025: net cash outflow of CHF -1.6 million).

Assets and liabilities
Intangible assets decreased by CHF -2.5 million to CHF 61.4 million, reflecting amortization in the period.

Total assets decreased by CHF -0.9 million to CHF 147.2 million. This is a result of a CHF 19.4 million increase in cash, offset by a decrease of trade receivables.

Total liabilities decreased by CHF -6.5 million to CHF 153.4 million driven primarily by the conversions of the convertible bond as well as payments of the Company’s outstanding debt balances.

Shareholders’ equity
Total consolidated equity as of June 30, 2026, was CHF -6.2 million compared to CHF -11.8 million as of December 31, 2025.

Share capital, treasury shares and warrants
As of June 30, 2026, issued share capital consisted of 15,642,856 shares with a total nominal value of CHF 1,564,285.60 (nominal value CHF 0.10 per share), and the Company held 639,204 treasury shares with total nominal value of CHF 63,920.40 for future equity-based financings. The Company also had 695,044 warrants in issue, comprising 236,540 at a strike price of CHF 11.0975, expiring August 12, 2029 and 458,504 at a strike price of CHF 20, which expired September 22,2026

Interim Consolidated Balance Sheet

In CHF thousands     Jun 30, 2026   Dec 31, 2025  
      (unaudited)   (restated)  
Assets            
             
Tangible assets     1,698   2,010  
             
Intangible assets     61,428   63,935  
             
Financial assets long-term     319   315  
             
Noncurrent deferred loss on financial instruments     227   1,584  
             
Noncurrent assets     63,672   67,844  
             
             
Current deferred loss on financial instruments     4,445   6,315  
             
Prepaid expenses     1,228   580  
             
Inventories     24,636   24,868  
             
Trade and other receivables     11,483   26,038  
             
Cash and cash equivalents     41,769   22,440  
             
Current assets     83,561   80,241  
             
             
Total assets     147,233   148,085  
             
             
Equity and liabilities            
             
Share capital     1,564   1,402  
             
Capital reserves and share premium     678,844   651,963  
             
Accumulated losses     (685,455)   (663,929)  
             
Employee benefit reserve     (898)   (1,017)  
             
Treasury shares     (64)   (62)  
             
Translation differences     (164)   (173)  
             
Total equity     (6,173)   (11,816)  
             
             
Noncurrent payables     23,727   7,616  
             
Noncurrent term loans     29,158   30,029  
             
Noncurrent royalty purchase agreements     40,441   39,934  
             
Noncurrent derivative financial instruments     1,212   1,532  
             
Noncurrent lease liabilities     1,091   1,369  
             
Noncurrent contract liabilities     2,899   3,156  
             
Pension liabilities     6,554   6,516  
             
Noncurrent liabilities, restated     105,082   90,152  
             
             
Trade and other payables     7,032   18,005  
             
Accrued expenses     13,132   19,404  
             
Income tax payable     1,074   893  
             
Current term loans     3,452   2,704  
             
Current royalty purchase agreements     4,961   7,153  
             
Current lease liabilities     558   588  
             
Current convertible bonds     7,016   14,259  
             
Current contract liabilities     6,241   139  
             
Current derivative financial instruments     2,807   4,874  
             
Current warrant financial instruments     2,051   1,730  
             
Current liabilities, restated     48,324   69,749  
             
             
Total liabilities     153,406   159,901  
             
             
Total equity and liabilities     147,233   148,085  
             

Interim Consolidated Income Statement

In CHF thousands (except per share data)     Six months ended June 30,  
      2026   2025  
      (unaudited)   (unaudited)  
             
Net sales     17,156   11,577  
             
Revenue from outlicensing transactions     29,103   6,548  
             
Net sales to licensing partners     2,071   5,888  
             
Revenue from contracts with customers     48,330   24,013  
             
             
Cost of sales     (30,017)   (32,123)  
             
Of which amortization intangible assets     (2,491)   (2,491)  
             
Of which royalties payable     (5,405)   (3,728)  
             
Of which milestones payable     (17,958)   (20,337)  
             
             
Other operating income     132   –  
             
             
Development     (9,914)   (11,693)  
             
Marketing and sales     (6,227)   (6,804)  
             
General and administrative     (8,868)   (8,837)  
             
Operating expenses     (25,007)   (27,334)  
             
             
Operating result     (6,562)   (35,444)  
             
             
Financial income     6,260   8,116  
             
Financial expenses     (21,193)   (11,429)  
             
Result before taxes     (21,495)   (38,757)  
             
             
Income taxes     (31)   (75)  
             
             
Net result     (21,526)   (38,832)  
             
             
Basic and diluted net result per share (in CHF)     (1.50)   (3.04)  
             

Interim Consolidated Statement of Cash Flows

In CHF thousands     Six months ended June 30,  
      2026   2025  
      (unaudited)   (unaudited)  
             
Result before taxes     (21,495)   (38,757)  
             
Depreciation of tangible assets     350   331  
             
Amortization of intangible assets     2,507   2,507  
             
Share-based compensation     1,945   2,335  
             
Change in fair value of financial instruments, net     3,543   (4,052)  
             
Change in pension liabilities     157   428  
             
Change in contract liabilities     5,945   (42)  
             
Change in net working capital     13,186   14,211  
             
Financial result net of change in fair value of financial instruments     10,632   4,408  
             
Interest received     –   355  
             
Interest paid     (1,945)   (2,322)  
             
Net cash flow from/(used in) operating activities     14,825   (20,598)  
             
             
Investments in tangible assets     (38)   (71)  
             
Net cash flow from/(used in) investing activities     (42)   (71)  
             
             
Proceeds from shares sold through private placements     8,080   –  
             
Proceeds from exercise of equity rights     157   103  
             
Repayments of royalty purchase liability     (1,379)   (1,430)  
             
Repayments of term loan     (2,419)   –  
             
Payment of lease liabilities     (308)   (290)  
             
Net cash flow from/(used in) financing activities     4,131   (1,617)  
             
             
Effects of exchange rate changes on cash and cash equivalents     415   (242)  
             
Net increase/(decrease) in cash and cash equivalents     19,329   (22,528)  
             
             
Cash and cash equivalents at January 1     22,440   40,925  
             
Cash and cash equivalents at June 30     41,769   18,397  
             

  • The All-Way SUV iCAUR V25 carries forward iCAUR’s iconic boxy design, featuring a near 1:1 body ratio, classic round headlamps and a wider, more substantial tire profile, further expressing the brand’s Future-Classic design philosophy.
  • Equipped with the i-AWD (Intelligent Electric All-Wheel-Drive) system, the iCAUR V25 offers multiple powertrain options, including REEV and BEV, balancing urban commuting and outdoor exploration to deliver richer, and more flexible all-scenario mobility options.
  • With open ecosystem interfaces, personalized expansion space and diverse lifestyle scenarios, the iCAUR V25 further extends the connection between the vehicle and users’ lives. During the summit, the V25 will appear alongside multiple modified vehicles, showcasing more possibilities for integrating the vehicle into different lifestyles.

WUHU, China, Sept. 30, 2026 (GLOBE NEWSWIRE) — The iCAUR V series is set to welcome a new member. The All-Way SUV iCAUR V25 will make its official debut on October 19 during the 2026 iCAUR International User Summit in Wuhu, China, appearing alongside the iCAUR V23 and iCAUR V27 for global users and media, further expanding the iCAUR V series lineup.

As the latest member of the iCAUR V series, the V25 carries forward the brand’s iconic boxy design DNA while further integrating the Future-Classic design philosophy. It also offers multiple powertrain options, including REEV and BEV, and is equipped with the i-AWD system. Combined with open ecosystem interfaces and personalized expansion space, the V25 delivers a richer all-scenario mobility experience.

An Unforgettable Boxy Silhouette, Defining Future-Classic Design

The iCAUR V25 carries forward iCAUR’s unforgettable classic boxy silhouette, with a near 1:1 body ratio and classic round headlamps creating a squared, upright and highly distinctive visual stance. Paired with a wider, more substantial tire profile beyond its class, it presents a high-stance design that embodies “Confident Stance.”

Its classic boxy design further integrates with future-oriented design language, giving full expression of the Future-Classic design philosophy. Classic is not a simple replication of the past, but rather a response to present and future lifestyles through new design language while preserving distinctive design identity.

iCAUR V25 Exterior 1

[iCAUR V25 Exterior]

i-AWD with Multiple Powertrain Options, Seamless Switch Between Urban and Outdoor Drives

Facing diverse mobility scenarios such as urban commuting and outdoor exploration, the iCAUR V25 offers richer powertrain options. The Golden REEV (Range-Extended Electric Vehicle) powertrain delivers a fuel-and-electric mobility experience, enabling more flexible switching between daily commuting and long-distance travel. A BEV (Battery Electric Vehicle) option is also available for the V25, allowing users to freely choose the powertrain that suits their lifestyle and mobility needs.

The iCAUR V25 is also equipped with the class-leading i-AWD system, tackling diverse road conditions from urban roads to suburban exploration with stronger all-scenario capability. Whether for daily urban commuting or exploring farther outdoors, the V25 confidently handles diverse mobility scenarios. Reliable body safety provides trustworthy assurance for every journey.

iCAUR V25 Exterior 2

[iCAUR V25 Exterior]

From Mobility Tool to Life Companion, Expanding Life’s Boundaries on Your Terms

For iCAUR, a vehicle is more than a means of getting from place to place. It is a way for users to explore and define life on their own terms.

Carrying forward iCAUR’s longstanding philosophy, of user co-creation, the V25 evolves from a mobility tool into a life companion. Its rich ecosystem interfaces and personalized modification space allow camping, cycling, outdoor exploration, towing and more lifestyles to integrate naturally. The high view, spacious, and flexible cabin leaves more possibilities for loading and use across different scenarios.

The V25 does not seek to define how users should use a vehicle, but rather leaves more choices to users. It can be a daily commuting partner or a weekend outdoor exploration companion; it can also retain its original character or integrate into users’ unique interests and lifestyles through different designs and functional expansions.

For iCAUR users, a vehicle is therefore not just a product, but an expression of personal lifestyle.

iCAUR V25 Interior 1

[iCAUR V25 Interior]

Every iCAUR Has Its Own Story

Different users build unique connections with their iCAUR through different interests, experiences and lifestyles. Behind every iCAUR, there can be a different story; and every user is able to define their vehicle in their own way.

From the V23 to the V27, and now to the V25, the iCAUR V series continues to enrich not only the product lineup, but also the possibilities for exploration, expression and creation for users with different lifestyles.

iCAUR V25 Interior 2

[iCAUR V25 Interior]

Serena Wang

Email: wangjieyun2@mychery.com

Website: iCAUR GLOBAL WEB

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/6796c116-8eaa-4c25-ab79-9088b7deb3f7

https://www.globenewswire.com/NewsRoom/AttachmentNg/a78da46a-080b-4afc-ac4d-0e22bb01ab76

https://www.globenewswire.com/NewsRoom/AttachmentNg/54973e40-d994-4882-ba94-b48d3127231d

https://www.globenewswire.com/NewsRoom/AttachmentNg/6658c0f6-e76c-4e2b-a378-37f11b94abf0

  • The All-Way SUV iCAUR V25 carries forward iCAUR’s iconic boxy design, featuring a near 1:1 body ratio, classic round headlamps and a wider, more substantial tire profile, further expressing the brand’s Future-Classic design philosophy.
  • Equipped with the i-AWD (Intelligent Electric All-Wheel-Drive) system, the iCAUR V25 offers multiple powertrain options, including REEV and BEV, balancing urban commuting and outdoor exploration to deliver richer, and more flexible all-scenario mobility options.
  • With open ecosystem interfaces, personalized expansion space and diverse lifestyle scenarios, the iCAUR V25 further extends the connection between the vehicle and users’ lives. During the summit, the V25 will appear alongside multiple modified vehicles, showcasing more possibilities for integrating the vehicle into different lifestyles.

WUHU, China, Sept. 30, 2026 (GLOBE NEWSWIRE) — The iCAUR V series is set to welcome a new member. The All-Way SUV iCAUR V25 will make its official debut on October 19 during the 2026 iCAUR International User Summit in Wuhu, China, appearing alongside the iCAUR V23 and iCAUR V27 for global users and media, further expanding the iCAUR V series lineup.

As the latest member of the iCAUR V series, the V25 carries forward the brand’s iconic boxy design DNA while further integrating the Future-Classic design philosophy. It also offers multiple powertrain options, including REEV and BEV, and is equipped with the i-AWD system. Combined with open ecosystem interfaces and personalized expansion space, the V25 delivers a richer all-scenario mobility experience.

An Unforgettable Boxy Silhouette, Defining Future-Classic Design

The iCAUR V25 carries forward iCAUR’s unforgettable classic boxy silhouette, with a near 1:1 body ratio and classic round headlamps creating a squared, upright and highly distinctive visual stance. Paired with a wider, more substantial tire profile beyond its class, it presents a high-stance design that embodies “Confident Stance.”

Its classic boxy design further integrates with future-oriented design language, giving full expression of the Future-Classic design philosophy. Classic is not a simple replication of the past, but rather a response to present and future lifestyles through new design language while preserving distinctive design identity.

iCAUR V25 Exterior 1

[iCAUR V25 Exterior]

i-AWD with Multiple Powertrain Options, Seamless Switch Between Urban and Outdoor Drives

Facing diverse mobility scenarios such as urban commuting and outdoor exploration, the iCAUR V25 offers richer powertrain options. The Golden REEV (Range-Extended Electric Vehicle) powertrain delivers a fuel-and-electric mobility experience, enabling more flexible switching between daily commuting and long-distance travel. A BEV (Battery Electric Vehicle) option is also available for the V25, allowing users to freely choose the powertrain that suits their lifestyle and mobility needs.

The iCAUR V25 is also equipped with the class-leading i-AWD system, tackling diverse road conditions from urban roads to suburban exploration with stronger all-scenario capability. Whether for daily urban commuting or exploring farther outdoors, the V25 confidently handles diverse mobility scenarios. Reliable body safety provides trustworthy assurance for every journey.

iCAUR V25 Exterior 2

[iCAUR V25 Exterior]

From Mobility Tool to Life Companion, Expanding Life’s Boundaries on Your Terms

For iCAUR, a vehicle is more than a means of getting from place to place. It is a way for users to explore and define life on their own terms.

Carrying forward iCAUR’s longstanding philosophy, of user co-creation, the V25 evolves from a mobility tool into a life companion. Its rich ecosystem interfaces and personalized modification space allow camping, cycling, outdoor exploration, towing and more lifestyles to integrate naturally. The high view, spacious, and flexible cabin leaves more possibilities for loading and use across different scenarios.

The V25 does not seek to define how users should use a vehicle, but rather leaves more choices to users. It can be a daily commuting partner or a weekend outdoor exploration companion; it can also retain its original character or integrate into users’ unique interests and lifestyles through different designs and functional expansions.

For iCAUR users, a vehicle is therefore not just a product, but an expression of personal lifestyle.

iCAUR V25 Interior 1

[iCAUR V25 Interior]

Every iCAUR Has Its Own Story

Different users build unique connections with their iCAUR through different interests, experiences and lifestyles. Behind every iCAUR, there can be a different story; and every user is able to define their vehicle in their own way.

From the V23 to the V27, and now to the V25, the iCAUR V series continues to enrich not only the product lineup, but also the possibilities for exploration, expression and creation for users with different lifestyles.

iCAUR V25 Interior 2

[iCAUR V25 Interior]

Serena Wang

Email: wangjieyun2@mychery.com

Website: iCAUR GLOBAL WEB

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/6796c116-8eaa-4c25-ab79-9088b7deb3f7

https://www.globenewswire.com/NewsRoom/AttachmentNg/a78da46a-080b-4afc-ac4d-0e22bb01ab76

https://www.globenewswire.com/NewsRoom/AttachmentNg/54973e40-d994-4882-ba94-b48d3127231d

https://www.globenewswire.com/NewsRoom/AttachmentNg/6658c0f6-e76c-4e2b-a378-37f11b94abf0

  • The All-Way SUV iCAUR V25 carries forward iCAUR’s iconic boxy design, featuring a near 1:1 body ratio, classic round headlamps and a wider, more substantial tire profile, further expressing the brand’s Future-Classic design philosophy.
  • Equipped with the i-AWD (Intelligent Electric All-Wheel-Drive) system, the iCAUR V25 offers multiple powertrain options, including REEV and BEV, balancing urban commuting and outdoor exploration to deliver richer, and more flexible all-scenario mobility options.
  • With open ecosystem interfaces, personalized expansion space and diverse lifestyle scenarios, the iCAUR V25 further extends the connection between the vehicle and users’ lives. During the summit, the V25 will appear alongside multiple modified vehicles, showcasing more possibilities for integrating the vehicle into different lifestyles.

WUHU, China, Sept. 30, 2026 (GLOBE NEWSWIRE) — The iCAUR V series is set to welcome a new member. The All-Way SUV iCAUR V25 will make its official debut on October 19 during the 2026 iCAUR International User Summit in Wuhu, China, appearing alongside the iCAUR V23 and iCAUR V27 for global users and media, further expanding the iCAUR V series lineup.

As the latest member of the iCAUR V series, the V25 carries forward the brand’s iconic boxy design DNA while further integrating the Future-Classic design philosophy. It also offers multiple powertrain options, including REEV and BEV, and is equipped with the i-AWD system. Combined with open ecosystem interfaces and personalized expansion space, the V25 delivers a richer all-scenario mobility experience.

An Unforgettable Boxy Silhouette, Defining Future-Classic Design

The iCAUR V25 carries forward iCAUR’s unforgettable classic boxy silhouette, with a near 1:1 body ratio and classic round headlamps creating a squared, upright and highly distinctive visual stance. Paired with a wider, more substantial tire profile beyond its class, it presents a high-stance design that embodies “Confident Stance.”

Its classic boxy design further integrates with future-oriented design language, giving full expression of the Future-Classic design philosophy. Classic is not a simple replication of the past, but rather a response to present and future lifestyles through new design language while preserving distinctive design identity.

iCAUR V25 Exterior 1

[iCAUR V25 Exterior]

i-AWD with Multiple Powertrain Options, Seamless Switch Between Urban and Outdoor Drives

Facing diverse mobility scenarios such as urban commuting and outdoor exploration, the iCAUR V25 offers richer powertrain options. The Golden REEV (Range-Extended Electric Vehicle) powertrain delivers a fuel-and-electric mobility experience, enabling more flexible switching between daily commuting and long-distance travel. A BEV (Battery Electric Vehicle) option is also available for the V25, allowing users to freely choose the powertrain that suits their lifestyle and mobility needs.

The iCAUR V25 is also equipped with the class-leading i-AWD system, tackling diverse road conditions from urban roads to suburban exploration with stronger all-scenario capability. Whether for daily urban commuting or exploring farther outdoors, the V25 confidently handles diverse mobility scenarios. Reliable body safety provides trustworthy assurance for every journey.

iCAUR V25 Exterior 2

[iCAUR V25 Exterior]

From Mobility Tool to Life Companion, Expanding Life’s Boundaries on Your Terms

For iCAUR, a vehicle is more than a means of getting from place to place. It is a way for users to explore and define life on their own terms.

Carrying forward iCAUR’s longstanding philosophy, of user co-creation, the V25 evolves from a mobility tool into a life companion. Its rich ecosystem interfaces and personalized modification space allow camping, cycling, outdoor exploration, towing and more lifestyles to integrate naturally. The high view, spacious, and flexible cabin leaves more possibilities for loading and use across different scenarios.

The V25 does not seek to define how users should use a vehicle, but rather leaves more choices to users. It can be a daily commuting partner or a weekend outdoor exploration companion; it can also retain its original character or integrate into users’ unique interests and lifestyles through different designs and functional expansions.

For iCAUR users, a vehicle is therefore not just a product, but an expression of personal lifestyle.

iCAUR V25 Interior 1

[iCAUR V25 Interior]

Every iCAUR Has Its Own Story

Different users build unique connections with their iCAUR through different interests, experiences and lifestyles. Behind every iCAUR, there can be a different story; and every user is able to define their vehicle in their own way.

From the V23 to the V27, and now to the V25, the iCAUR V series continues to enrich not only the product lineup, but also the possibilities for exploration, expression and creation for users with different lifestyles.

iCAUR V25 Interior 2

[iCAUR V25 Interior]

Serena Wang

Email: wangjieyun2@mychery.com

Website: iCAUR GLOBAL WEB

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/6796c116-8eaa-4c25-ab79-9088b7deb3f7

https://www.globenewswire.com/NewsRoom/AttachmentNg/a78da46a-080b-4afc-ac4d-0e22bb01ab76

https://www.globenewswire.com/NewsRoom/AttachmentNg/54973e40-d994-4882-ba94-b48d3127231d

https://www.globenewswire.com/NewsRoom/AttachmentNg/6658c0f6-e76c-4e2b-a378-37f11b94abf0

  • The All-Way SUV iCAUR V25 carries forward iCAUR’s iconic boxy design, featuring a near 1:1 body ratio, classic round headlamps and a wider, more substantial tire profile, further expressing the brand’s Future-Classic design philosophy.
  • Equipped with the i-AWD (Intelligent Electric All-Wheel-Drive) system, the iCAUR V25 offers multiple powertrain options, including REEV and BEV, balancing urban commuting and outdoor exploration to deliver richer, and more flexible all-scenario mobility options.
  • With open ecosystem interfaces, personalized expansion space and diverse lifestyle scenarios, the iCAUR V25 further extends the connection between the vehicle and users’ lives. During the summit, the V25 will appear alongside multiple modified vehicles, showcasing more possibilities for integrating the vehicle into different lifestyles.

WUHU, China, Sept. 30, 2026 (GLOBE NEWSWIRE) — The iCAUR V series is set to welcome a new member. The All-Way SUV iCAUR V25 will make its official debut on October 19 during the 2026 iCAUR International User Summit in Wuhu, China, appearing alongside the iCAUR V23 and iCAUR V27 for global users and media, further expanding the iCAUR V series lineup.

As the latest member of the iCAUR V series, the V25 carries forward the brand’s iconic boxy design DNA while further integrating the Future-Classic design philosophy. It also offers multiple powertrain options, including REEV and BEV, and is equipped with the i-AWD system. Combined with open ecosystem interfaces and personalized expansion space, the V25 delivers a richer all-scenario mobility experience.

An Unforgettable Boxy Silhouette, Defining Future-Classic Design

The iCAUR V25 carries forward iCAUR’s unforgettable classic boxy silhouette, with a near 1:1 body ratio and classic round headlamps creating a squared, upright and highly distinctive visual stance. Paired with a wider, more substantial tire profile beyond its class, it presents a high-stance design that embodies “Confident Stance.”

Its classic boxy design further integrates with future-oriented design language, giving full expression of the Future-Classic design philosophy. Classic is not a simple replication of the past, but rather a response to present and future lifestyles through new design language while preserving distinctive design identity.

iCAUR V25 Exterior 1

[iCAUR V25 Exterior]

i-AWD with Multiple Powertrain Options, Seamless Switch Between Urban and Outdoor Drives

Facing diverse mobility scenarios such as urban commuting and outdoor exploration, the iCAUR V25 offers richer powertrain options. The Golden REEV (Range-Extended Electric Vehicle) powertrain delivers a fuel-and-electric mobility experience, enabling more flexible switching between daily commuting and long-distance travel. A BEV (Battery Electric Vehicle) option is also available for the V25, allowing users to freely choose the powertrain that suits their lifestyle and mobility needs.

The iCAUR V25 is also equipped with the class-leading i-AWD system, tackling diverse road conditions from urban roads to suburban exploration with stronger all-scenario capability. Whether for daily urban commuting or exploring farther outdoors, the V25 confidently handles diverse mobility scenarios. Reliable body safety provides trustworthy assurance for every journey.

iCAUR V25 Exterior 2

[iCAUR V25 Exterior]

From Mobility Tool to Life Companion, Expanding Life’s Boundaries on Your Terms

For iCAUR, a vehicle is more than a means of getting from place to place. It is a way for users to explore and define life on their own terms.

Carrying forward iCAUR’s longstanding philosophy, of user co-creation, the V25 evolves from a mobility tool into a life companion. Its rich ecosystem interfaces and personalized modification space allow camping, cycling, outdoor exploration, towing and more lifestyles to integrate naturally. The high view, spacious, and flexible cabin leaves more possibilities for loading and use across different scenarios.

The V25 does not seek to define how users should use a vehicle, but rather leaves more choices to users. It can be a daily commuting partner or a weekend outdoor exploration companion; it can also retain its original character or integrate into users’ unique interests and lifestyles through different designs and functional expansions.

For iCAUR users, a vehicle is therefore not just a product, but an expression of personal lifestyle.

iCAUR V25 Interior 1

[iCAUR V25 Interior]

Every iCAUR Has Its Own Story

Different users build unique connections with their iCAUR through different interests, experiences and lifestyles. Behind every iCAUR, there can be a different story; and every user is able to define their vehicle in their own way.

From the V23 to the V27, and now to the V25, the iCAUR V series continues to enrich not only the product lineup, but also the possibilities for exploration, expression and creation for users with different lifestyles.

iCAUR V25 Interior 2

[iCAUR V25 Interior]

Serena Wang

Email: wangjieyun2@mychery.com

Website: iCAUR GLOBAL WEB

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/6796c116-8eaa-4c25-ab79-9088b7deb3f7

https://www.globenewswire.com/NewsRoom/AttachmentNg/a78da46a-080b-4afc-ac4d-0e22bb01ab76

https://www.globenewswire.com/NewsRoom/AttachmentNg/54973e40-d994-4882-ba94-b48d3127231d

https://www.globenewswire.com/NewsRoom/AttachmentNg/6658c0f6-e76c-4e2b-a378-37f11b94abf0

Gross Revenue of US$165.72 Million and Cash Cost of US$1,243/Oz

VANCOUVER, British Columbia, Sept. 30, 2026 (GLOBE NEWSWIRE) — Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) “Monument” or the “Company” today announced its annual financial results for the year ended June 30, 2026 (“Fiscal 2026” or “FY 2026”). All amounts are in United States dollars unless otherwise indicated (refer to www.sedar.com for full financial results).

Fiscal 2026 gold production generated gross revenue of $165.72 million, compared to $98.64 million. Net earnings of $68.80 million, or $0.20 per share, up from $37.54 million, or $0.11 per share, in the prior year. The Company’s financial position has improved, with cash flow rising to $82.21 million from $48.65 million last year, cash reserves increasing to $109.56 million from $45.94 million and working capital strengthening to $122.86 million from $58.54 million.

Cathy Zhai, the President and CEO commented: “Fiscal 2026 strengthened Monument’s financial foundation while Selinsing continued to generate substantial cash flow. Our priorities are clear: sustain Selinsing production, accelerate exploration to extend mine life, advance Murchison toward a potential second source of cash flow, and deploy capital selectively toward growth and shareholder value.”

Fiscal Year 2026 Highlights:

  • The earnings per share reached $0.20 per share (FY2025: $0.11/share);
  • Net profit of $68.80 million (FY 2025: $37.54 million);
  • Gross margin of $109.76 million for FY 2026, a 69% increase compared to $65.11 million in FY 2025;
  • $109.56 million of Cash and Cash Equivalent and short investment comprised Cash & Cash Equivalent of $37.10 million (FY2025: $45.90 million) and $72.46 million of term deposit (FY2025: nil) invested over 90 to 270 days.
  • Working capital of $122.86 million, an increase of $64.32 million from $58.54 million at the end of June 30, 2025;
  • Production performance:
    • 44,942 ounces of gold produced during the year (FY 2025: 38,530 ounces);
    • 45,010 ounces of gold sold at an average realized price of $4,280/oz for a gross revenue of $165.72 million (FY 2025: 41,183 ounces sold at an average realized price of $2,947/oz for gross revenue of $98.64 million);
    • Cash cost of $1,243 per ounce sold (FY 2025: $814/oz), reflecting higher mining cost as mining went deeper, increased royalty rates and higher royalty payment per ounce corresponding to higher gold price; partially offset by increased gold recovery rates;
    • All in sustaining cost of $1,446 per ounce sold for FY 2026, compared to $1,093/oz in FY 2025.
  • Extensive exploration drilling activities were carried out at Selinsing during FY 2026 targeting potential resource growth and future mine life extension opportunities;
  • A one-time Special Dividend of $5.04 million (CAD$6.91 million) paid to shareholders on January 19, 2026, reflecting the Company’s commitment to shareholder value.
  • On February 18, 2026, the Company was recognized as one of the top-performing companies on the TSX Venture Exchange (“TSXV”) for 2025, earning a place on the 2026 TSX Venture 50™ list.

Fourth Quarter Operation Highlights:

  • During Q4 FY2026, the Selinsing Gold Mine produced 9,902 ounces of gold, with sales of 9,581 ounces gold in concentrate yielding gross revenue of $37.05 million, at a realized gold price per ounce of $4,349 (London PM average gold price: $4,506/oz), compared to gross revenue of $39.63 million from 14,527 ounces sold at a realized gold price per ounce of $3,368 (London PM average gold price: $3,280/oz) for the three months ended June 30, 2025;
  • Cash cost per ounce for gold concentrate sold at $1,433/oz (Q4 FY2025: $701/oz), reflecting higher mining cost as mining went deeper, higher royalty per ounce of gold sold due to higher royalty rate and higher gold price;
  • AISC increased to $1,898/oz (Q4 FY2025: $853/oz).

Fourth Quarter and Fiscal Year 2026 Production and Financial Highlights 

  Three months ended June 30, Year ended June 30,  
  2026 2025   2026 2025
Production        
Ore mined (tonnes) 222,835 193,481   868,712 726,012
Waste removed (tonnes) 1,839,377 2,138,118   7,841,692 8,592,126
Gold Sulphide Production        
Ore processed (tonnes) 234,007 235,264   941,525 786,241
Average mill feed grade (g/t) 1.48 1.82   1.66 1.79
Processing recovery rate (%) 88.77 89.50   89.49 85.32
Gold produced (oz) 9,902 12,315   44,942 38,530
Gold sold (oz) 9,581 14,527   45,010 41,183
         
Financial (expressed in thousands of US$) $ $ $ $
Revenue 37,046 39,625   165,715 98,639
Gross margin from mining operations 23,307 29,449   109,759 65,112
Net Income before other items 18,446 24,754   88,128 51,075
Net Income 15,489 20,837   68,795 37,536
Cash flows provided by operations 13,855 18,932   82,208 48,652
Working capital 122,858 58,544   122,858 58,544
         
Earnings per share – basic and diluted (US$/share) 0.04 0.06   0.20 0.11
         
Weighted average gold price US$/oz US$/oz US$/oz US$/oz
Realized price – sulphide production 4,349 3,368   4,280 2,947
         
Cash cost per ounce sold        
Mining 387 241   343 239
Processing 341 262   291 285
Royalties 575 97   500 192
Rehabilitation fund levy 39 26   37 24
Operations 91 75   72 74
Total cash cost per ounce sold(1) 1433 701   1243 814
Operation expenses 2 1   1 3
Corporate expenses 28 (3 ) 8 10
Accretion of asset retirement obligation 6 4   5 6
Exploration and evaluation expenditures 44 25   11 15
Sustaining capital expenditures 385 125   178 245
Total all-in sustaining costs per ounce sold(2) 1,898 853   1,446 1,093

(1)  Total cash cost for sulphide plant production includes production costs such as mining, processing, tailing facility maintenance and camp administration, royalties, rehabilitation fund levy, and operating costs such as storage, temporary mine production closure, community development cost and property fees. Cash costs exclude amortization, depletion, accretion expenses, operation expenses, capital costs, exploration costs and corporate administration costs.
(2)  All-in sustaining cost per ounce includes total cash costs, operation expenses, and adds sustaining capital expenditures, corporate administrative expenses for the Selinsing Gold Mine including share-based compensation, exploration and evaluation costs, and accretion of asset retirement obligations. Certain other cash expenditures, including tax payments and acquisition costs, are not included.

GOLD PRODUCTION RESULTS

Annual gold production

  • During the year ended June 30, 2026, 44,942 ounces of gold, after the adjustment of 2,536 ounces of gold production, resulting from the processing of 941,525 tonnes of ore at an average feed grade of 1.66 g/t. During the year ended June 30, 2025, 38,530 ounces of gold were produced from 786,241 tonnes of ore processed through the flotation plant at an average feed grade of 1.79 g/t and a recovery rate at 85.32%.
  • Mining activities continued to focus on Buffalo Reef and Felda Block 7, supplying ore to the Selinsing sulphide plant during the year ended June 30, 2026. A total of 868,712 tonnes of ore was mined (FY 2025: 726,012 tonnes) and 7,841,692 tonnes of waste (FY 2025: 8,592,126 tonnes) moved at a lower stripping ratio of 9.03 compared to 11.83 in the prior year primarily as the main orebody of sulphide ores was reached.

Fourth quarter gold production

Gold produced from the sulphide flotation plant was 9,902 ounces, including an additional 603 ounces adjustment, in Q4 FY 2026, resulting from the processing of 234,007 tonnes of ore at a feed grade of 1.48 g/t gold and a recovery rate of 88.77%. (Q4 FY 2025: 12,315 ounces).

FINANCIAL RESULTS

Fiscal 2026 financial results

  • During the year ended June 30, 2026, revenue from sulphide gold production was $165.72 million (FY 2025: $98.64 million), as a result of the sale of 45,010 ounces of gold concentrate at a realized gold price of $4.280 per ounce (FY 2025: 41,183 ounces at $2,947/oz).
  • The gross margin was higher at $109.76 million (FY 2025: $65.11 million) due to increased gold concentrate sales at higher realized gold prices.
  • The cash cost for sulphide flotation gold concentrate production was $1,243 per ounce for FY 2026 (FY 2025: $814 per ounce for gold concentrate), led by higher mining costs, an increased royalty rate and higher royalty costs per ounce associated with stronger realized gold prices, and lower feed grades, partially offset by improved recovery rates.
  • As of June 30, 2026, cash reserves totaled $109.56 million, comprising cash and cash equivalents of $37.10 million and short-term investment – term deposits of $72.46 million, an increase of $63.62 million from cash and cash equivalents of $45.94 million as of June 30, 2025.
  • Cash used in investing activities of $85.93 million (FY 2025: $13.54 million) represented $72.46 million in short-term investments (FY 2025: nil), $11.61 million invested in Selinsing mainly for cutback and stripping activities, expansion drilling and geological work, Flotation Plant improvements, and Tailings Storage Facility (“TSF”) upgrades (FY 2025: $12.29 million), and $1.86 million (FY 2025: $1.25 million) invested in Murchison exploration and evaluation projects.

Quarter four financial results

  • Q4 FY 2026 revenue from gold concentrate production was $37.05 million, derived from the sale of 9,581 ounces of gold at an average realized price of $4,349 per ounce (Q4 FY 2025:39.63 million from 14,527 ounces of gold at $3,368/oz).
  • Mining operations before non-cash amortization and depreciation generated a gross margin of $23.31 million, decrease from $29.45 million in Q4 FY2025 and resulting from less gold concentrate sales, offset by a higher realized gold price. After accounting for operating expenses, non-cash depreciation and accretion expenses totaling $3.86 million (Q4 FY 2025: $4.36 million), the income from mining operations was $19.45 million (Q4 FY 2025: $25.09 million).
  • Total production costs during Q4 FY2026 were $13.74 million compared to $10.18 million during Q4 FY2025. The increase was due to higher royalties from royalty rate and gold price increase and higher rehabilitation fund levy from more revenue.
  • The cash cost per gold ounce sold from the sulphide operations was $1,433 for Q4 FY2026 (Q4 FY2025: $701 for sulphide operations). The increases were primarily attributable to higher royalty and rehabilitation fund levy associated with significantly stronger realized gold prices during the quarter, as well as higher mining costs driven by increased ore mined and deeper pits and additional Sales and Service Tax (“SST”) implemented by the government on mining-related services, higher milling costs from more transition ore processed, and the payment of annual bonuses.

MINE DEVELOPMENT

Selinsing Gold Mine

During FY 2026, development at Selinsing encompassed cutbacks and pre-stripping activities, drilling and geological work, tailings storage facility updates, gold concentrate warehouse expansion and flotation plant improvements. Bench scale test work was conducted for improved gold and antimony recovery. Construction of the warehouse extension was completed and extended the capacity to 7,000 Wet Metric Tonne (“WMT”) from 4,000 WMT. The TSF interim elevation of 543 mRL will provide an additional capacity of around 1.5 million tonnes, equivalent to 20 months of tailings discharge. The Computerized Maintenance Management System was successfully implemented and will contribute positively to operational efficiency, cost control, and overall asset performance.

Murchison Gold Project

At the Murchison Project, the Company continued technical and development studies, including a review of Process Design Criteria assessments including new plant options and a Statement of Work for future processing expansion opportunities, for ongoing project evaluation and development planning. Technical and economic studies continued to advance in support of a potential production restart. Other project advance activities include regulatory compliance and environmental surveys.

Exploration

Malaysia

The Buffalo Reef exploration drilling program progressed during the fourth quarter of FY 2026 with 43 holes completed and 5,868.60 metres drilled. The drilling program targeted potential extensions of mineralization outside of the current pit-shell, which may support an extension of the mine life, subject to further studies. By the end of the fourth quarter of FY 2026, a total of 18,913.10 metres had been drilled as part of the resource expansion program, and a total of 15,158 samples were prepared and dispatched to the assay laboratory.

Western Australia

No field exploration was undertaken at the Murchison Project during Q4 2026. The Company reviewed the historic resources at the Gabanintha Gold Project, including analysis of historical data. A desktop assessment identified step-out drilling targets with potential to expand the currently known mineralization, which remains open along strike. Confirmation drilling is planned to commence when regulatory compliance is met.

_______________________________________

About Monument

Monument Mining Limited (TSX-V: MMY, FSE: D7Q1) is an established Canadian gold producer that 100% owns and operates the Selinsing Gold Mine in Malaysia and the Murchison Gold Project in the Murchison area of Western Australia. It has 20% interest in Tuckanarra Gold Project, jointly owned by Odyssey Gold Ltd in the same region. The Company employs approximately 295 people in both regions and is committed to the highest standards of environmental management, social responsibility, including health and safety for its employees and neighboring communities and good corporate governance.

Cathy Zhai, President and CEO
Monument Mining Limited
Suite 1580 -1100 Melville Street
Vancouver, BC V6E 4A6

FOR FURTHER INFORMATION visit the company web site at www.monumentmining.com or contact:

Richard Cushing, MMY Vancouver         T: +1-604-638-1661 x102         rcushing@monumentmining.com

“Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”

Disclaimer Regarding Forward-Looking Statements

This news release includes statements containing forward-looking information about Monument, its business and future plans (“forward-looking statements”). Forward-looking statements are statements that involve expectations, plans, objectives or future events that are not historical facts and include the Company’s plans with respect to its mineral projects, expectations regarding the Company’s continuing ability to source explosives from suppliers and the timing and results of the other proposed programs and events referred to in this news release. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. The forward-looking statements in this news release are subject to various risks, uncertainties and other factors that could cause actual results or achievements to differ materially from those expressed or implied by the forward-looking statements. These risks and certain other factors include, without limitation: risks related to general business, economic, competitive, geopolitical and social uncertainties; uncertainties regarding the results of current exploration activities; uncertainties in the progress and timing of development activities, uncertainties and risks related to the Company’s ability to source explosives from suppliers; foreign operations risks; other risks inherent in the mining industry and other risks described in the management discussion and analysis of the Company and the technical reports on the Company’s projects, all of which are available under the profile of the Company on SEDAR at www.sedar.com. Material factors and assumptions used to develop forward-looking statements in this news release include: expectations regarding the estimated cash cost per ounce of gold production and the estimated cash flows which may be generated from the operations, general economic factors and other factors that may be beyond the control of Monument; assumptions and expectations regarding the results of exploration on the Company’s projects; assumptions regarding the future price of gold of other minerals; the timing and amount of estimated future production; assumptions regarding the timing and results of development activities; expectations that the Company will continue to be able to source explosives from suppliers in a timely manner; costs of future activities; capital and operating expenditures; success of exploration activities; mining or processing issues; exchange rates; and all of the factors and assumptions described in the management discussion and analysis of the Company and the technical reports on the Company’s projects, all of which are available under the profile of the Company on SEDAR at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements, except in accordance with applicable securities laws.

Gross Revenue of US$165.72 Million and Cash Cost of US$1,243/Oz

VANCOUVER, British Columbia, Sept. 30, 2026 (GLOBE NEWSWIRE) — Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) “Monument” or the “Company” today announced its annual financial results for the year ended June 30, 2026 (“Fiscal 2026” or “FY 2026”). All amounts are in United States dollars unless otherwise indicated (refer to www.sedar.com for full financial results).

Fiscal 2026 gold production generated gross revenue of $165.72 million, compared to $98.64 million. Net earnings of $68.80 million, or $0.20 per share, up from $37.54 million, or $0.11 per share, in the prior year. The Company’s financial position has improved, with cash flow rising to $82.21 million from $48.65 million last year, cash reserves increasing to $109.56 million from $45.94 million and working capital strengthening to $122.86 million from $58.54 million.

Cathy Zhai, the President and CEO commented: “Fiscal 2026 strengthened Monument’s financial foundation while Selinsing continued to generate substantial cash flow. Our priorities are clear: sustain Selinsing production, accelerate exploration to extend mine life, advance Murchison toward a potential second source of cash flow, and deploy capital selectively toward growth and shareholder value.”

Fiscal Year 2026 Highlights:

  • The earnings per share reached $0.20 per share (FY2025: $0.11/share);
  • Net profit of $68.80 million (FY 2025: $37.54 million);
  • Gross margin of $109.76 million for FY 2026, a 69% increase compared to $65.11 million in FY 2025;
  • $109.56 million of Cash and Cash Equivalent and short investment comprised Cash & Cash Equivalent of $37.10 million (FY2025: $45.90 million) and $72.46 million of term deposit (FY2025: nil) invested over 90 to 270 days.
  • Working capital of $122.86 million, an increase of $64.32 million from $58.54 million at the end of June 30, 2025;
  • Production performance:
    • 44,942 ounces of gold produced during the year (FY 2025: 38,530 ounces);
    • 45,010 ounces of gold sold at an average realized price of $4,280/oz for a gross revenue of $165.72 million (FY 2025: 41,183 ounces sold at an average realized price of $2,947/oz for gross revenue of $98.64 million);
    • Cash cost of $1,243 per ounce sold (FY 2025: $814/oz), reflecting higher mining cost as mining went deeper, increased royalty rates and higher royalty payment per ounce corresponding to higher gold price; partially offset by increased gold recovery rates;
    • All in sustaining cost of $1,446 per ounce sold for FY 2026, compared to $1,093/oz in FY 2025.
  • Extensive exploration drilling activities were carried out at Selinsing during FY 2026 targeting potential resource growth and future mine life extension opportunities;
  • A one-time Special Dividend of $5.04 million (CAD$6.91 million) paid to shareholders on January 19, 2026, reflecting the Company’s commitment to shareholder value.
  • On February 18, 2026, the Company was recognized as one of the top-performing companies on the TSX Venture Exchange (“TSXV”) for 2025, earning a place on the 2026 TSX Venture 50™ list.

Fourth Quarter Operation Highlights:

  • During Q4 FY2026, the Selinsing Gold Mine produced 9,902 ounces of gold, with sales of 9,581 ounces gold in concentrate yielding gross revenue of $37.05 million, at a realized gold price per ounce of $4,349 (London PM average gold price: $4,506/oz), compared to gross revenue of $39.63 million from 14,527 ounces sold at a realized gold price per ounce of $3,368 (London PM average gold price: $3,280/oz) for the three months ended June 30, 2025;
  • Cash cost per ounce for gold concentrate sold at $1,433/oz (Q4 FY2025: $701/oz), reflecting higher mining cost as mining went deeper, higher royalty per ounce of gold sold due to higher royalty rate and higher gold price;
  • AISC increased to $1,898/oz (Q4 FY2025: $853/oz).

Fourth Quarter and Fiscal Year 2026 Production and Financial Highlights 

  Three months ended June 30, Year ended June 30,  
  2026 2025   2026 2025
Production        
Ore mined (tonnes) 222,835 193,481   868,712 726,012
Waste removed (tonnes) 1,839,377 2,138,118   7,841,692 8,592,126
Gold Sulphide Production        
Ore processed (tonnes) 234,007 235,264   941,525 786,241
Average mill feed grade (g/t) 1.48 1.82   1.66 1.79
Processing recovery rate (%) 88.77 89.50   89.49 85.32
Gold produced (oz) 9,902 12,315   44,942 38,530
Gold sold (oz) 9,581 14,527   45,010 41,183
         
Financial (expressed in thousands of US$) $ $ $ $
Revenue 37,046 39,625   165,715 98,639
Gross margin from mining operations 23,307 29,449   109,759 65,112
Net Income before other items 18,446 24,754   88,128 51,075
Net Income 15,489 20,837   68,795 37,536
Cash flows provided by operations 13,855 18,932   82,208 48,652
Working capital 122,858 58,544   122,858 58,544
         
Earnings per share – basic and diluted (US$/share) 0.04 0.06   0.20 0.11
         
Weighted average gold price US$/oz US$/oz US$/oz US$/oz
Realized price – sulphide production 4,349 3,368   4,280 2,947
         
Cash cost per ounce sold        
Mining 387 241   343 239
Processing 341 262   291 285
Royalties 575 97   500 192
Rehabilitation fund levy 39 26   37 24
Operations 91 75   72 74
Total cash cost per ounce sold(1) 1433 701   1243 814
Operation expenses 2 1   1 3
Corporate expenses 28 (3 ) 8 10
Accretion of asset retirement obligation 6 4   5 6
Exploration and evaluation expenditures 44 25   11 15
Sustaining capital expenditures 385 125   178 245
Total all-in sustaining costs per ounce sold(2) 1,898 853   1,446 1,093

(1)  Total cash cost for sulphide plant production includes production costs such as mining, processing, tailing facility maintenance and camp administration, royalties, rehabilitation fund levy, and operating costs such as storage, temporary mine production closure, community development cost and property fees. Cash costs exclude amortization, depletion, accretion expenses, operation expenses, capital costs, exploration costs and corporate administration costs.
(2)  All-in sustaining cost per ounce includes total cash costs, operation expenses, and adds sustaining capital expenditures, corporate administrative expenses for the Selinsing Gold Mine including share-based compensation, exploration and evaluation costs, and accretion of asset retirement obligations. Certain other cash expenditures, including tax payments and acquisition costs, are not included.

GOLD PRODUCTION RESULTS

Annual gold production

  • During the year ended June 30, 2026, 44,942 ounces of gold, after the adjustment of 2,536 ounces of gold production, resulting from the processing of 941,525 tonnes of ore at an average feed grade of 1.66 g/t. During the year ended June 30, 2025, 38,530 ounces of gold were produced from 786,241 tonnes of ore processed through the flotation plant at an average feed grade of 1.79 g/t and a recovery rate at 85.32%.
  • Mining activities continued to focus on Buffalo Reef and Felda Block 7, supplying ore to the Selinsing sulphide plant during the year ended June 30, 2026. A total of 868,712 tonnes of ore was mined (FY 2025: 726,012 tonnes) and 7,841,692 tonnes of waste (FY 2025: 8,592,126 tonnes) moved at a lower stripping ratio of 9.03 compared to 11.83 in the prior year primarily as the main orebody of sulphide ores was reached.

Fourth quarter gold production

Gold produced from the sulphide flotation plant was 9,902 ounces, including an additional 603 ounces adjustment, in Q4 FY 2026, resulting from the processing of 234,007 tonnes of ore at a feed grade of 1.48 g/t gold and a recovery rate of 88.77%. (Q4 FY 2025: 12,315 ounces).

FINANCIAL RESULTS

Fiscal 2026 financial results

  • During the year ended June 30, 2026, revenue from sulphide gold production was $165.72 million (FY 2025: $98.64 million), as a result of the sale of 45,010 ounces of gold concentrate at a realized gold price of $4.280 per ounce (FY 2025: 41,183 ounces at $2,947/oz).
  • The gross margin was higher at $109.76 million (FY 2025: $65.11 million) due to increased gold concentrate sales at higher realized gold prices.
  • The cash cost for sulphide flotation gold concentrate production was $1,243 per ounce for FY 2026 (FY 2025: $814 per ounce for gold concentrate), led by higher mining costs, an increased royalty rate and higher royalty costs per ounce associated with stronger realized gold prices, and lower feed grades, partially offset by improved recovery rates.
  • As of June 30, 2026, cash reserves totaled $109.56 million, comprising cash and cash equivalents of $37.10 million and short-term investment – term deposits of $72.46 million, an increase of $63.62 million from cash and cash equivalents of $45.94 million as of June 30, 2025.
  • Cash used in investing activities of $85.93 million (FY 2025: $13.54 million) represented $72.46 million in short-term investments (FY 2025: nil), $11.61 million invested in Selinsing mainly for cutback and stripping activities, expansion drilling and geological work, Flotation Plant improvements, and Tailings Storage Facility (“TSF”) upgrades (FY 2025: $12.29 million), and $1.86 million (FY 2025: $1.25 million) invested in Murchison exploration and evaluation projects.

Quarter four financial results

  • Q4 FY 2026 revenue from gold concentrate production was $37.05 million, derived from the sale of 9,581 ounces of gold at an average realized price of $4,349 per ounce (Q4 FY 2025:39.63 million from 14,527 ounces of gold at $3,368/oz).
  • Mining operations before non-cash amortization and depreciation generated a gross margin of $23.31 million, decrease from $29.45 million in Q4 FY2025 and resulting from less gold concentrate sales, offset by a higher realized gold price. After accounting for operating expenses, non-cash depreciation and accretion expenses totaling $3.86 million (Q4 FY 2025: $4.36 million), the income from mining operations was $19.45 million (Q4 FY 2025: $25.09 million).
  • Total production costs during Q4 FY2026 were $13.74 million compared to $10.18 million during Q4 FY2025. The increase was due to higher royalties from royalty rate and gold price increase and higher rehabilitation fund levy from more revenue.
  • The cash cost per gold ounce sold from the sulphide operations was $1,433 for Q4 FY2026 (Q4 FY2025: $701 for sulphide operations). The increases were primarily attributable to higher royalty and rehabilitation fund levy associated with significantly stronger realized gold prices during the quarter, as well as higher mining costs driven by increased ore mined and deeper pits and additional Sales and Service Tax (“SST”) implemented by the government on mining-related services, higher milling costs from more transition ore processed, and the payment of annual bonuses.

MINE DEVELOPMENT

Selinsing Gold Mine

During FY 2026, development at Selinsing encompassed cutbacks and pre-stripping activities, drilling and geological work, tailings storage facility updates, gold concentrate warehouse expansion and flotation plant improvements. Bench scale test work was conducted for improved gold and antimony recovery. Construction of the warehouse extension was completed and extended the capacity to 7,000 Wet Metric Tonne (“WMT”) from 4,000 WMT. The TSF interim elevation of 543 mRL will provide an additional capacity of around 1.5 million tonnes, equivalent to 20 months of tailings discharge. The Computerized Maintenance Management System was successfully implemented and will contribute positively to operational efficiency, cost control, and overall asset performance.

Murchison Gold Project

At the Murchison Project, the Company continued technical and development studies, including a review of Process Design Criteria assessments including new plant options and a Statement of Work for future processing expansion opportunities, for ongoing project evaluation and development planning. Technical and economic studies continued to advance in support of a potential production restart. Other project advance activities include regulatory compliance and environmental surveys.

Exploration

Malaysia

The Buffalo Reef exploration drilling program progressed during the fourth quarter of FY 2026 with 43 holes completed and 5,868.60 metres drilled. The drilling program targeted potential extensions of mineralization outside of the current pit-shell, which may support an extension of the mine life, subject to further studies. By the end of the fourth quarter of FY 2026, a total of 18,913.10 metres had been drilled as part of the resource expansion program, and a total of 15,158 samples were prepared and dispatched to the assay laboratory.

Western Australia

No field exploration was undertaken at the Murchison Project during Q4 2026. The Company reviewed the historic resources at the Gabanintha Gold Project, including analysis of historical data. A desktop assessment identified step-out drilling targets with potential to expand the currently known mineralization, which remains open along strike. Confirmation drilling is planned to commence when regulatory compliance is met.

_______________________________________

About Monument

Monument Mining Limited (TSX-V: MMY, FSE: D7Q1) is an established Canadian gold producer that 100% owns and operates the Selinsing Gold Mine in Malaysia and the Murchison Gold Project in the Murchison area of Western Australia. It has 20% interest in Tuckanarra Gold Project, jointly owned by Odyssey Gold Ltd in the same region. The Company employs approximately 295 people in both regions and is committed to the highest standards of environmental management, social responsibility, including health and safety for its employees and neighboring communities and good corporate governance.

Cathy Zhai, President and CEO
Monument Mining Limited
Suite 1580 -1100 Melville Street
Vancouver, BC V6E 4A6

FOR FURTHER INFORMATION visit the company web site at www.monumentmining.com or contact:

Richard Cushing, MMY Vancouver         T: +1-604-638-1661 x102         rcushing@monumentmining.com

“Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”

Disclaimer Regarding Forward-Looking Statements

This news release includes statements containing forward-looking information about Monument, its business and future plans (“forward-looking statements”). Forward-looking statements are statements that involve expectations, plans, objectives or future events that are not historical facts and include the Company’s plans with respect to its mineral projects, expectations regarding the Company’s continuing ability to source explosives from suppliers and the timing and results of the other proposed programs and events referred to in this news release. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. The forward-looking statements in this news release are subject to various risks, uncertainties and other factors that could cause actual results or achievements to differ materially from those expressed or implied by the forward-looking statements. These risks and certain other factors include, without limitation: risks related to general business, economic, competitive, geopolitical and social uncertainties; uncertainties regarding the results of current exploration activities; uncertainties in the progress and timing of development activities, uncertainties and risks related to the Company’s ability to source explosives from suppliers; foreign operations risks; other risks inherent in the mining industry and other risks described in the management discussion and analysis of the Company and the technical reports on the Company’s projects, all of which are available under the profile of the Company on SEDAR at www.sedar.com. Material factors and assumptions used to develop forward-looking statements in this news release include: expectations regarding the estimated cash cost per ounce of gold production and the estimated cash flows which may be generated from the operations, general economic factors and other factors that may be beyond the control of Monument; assumptions and expectations regarding the results of exploration on the Company’s projects; assumptions regarding the future price of gold of other minerals; the timing and amount of estimated future production; assumptions regarding the timing and results of development activities; expectations that the Company will continue to be able to source explosives from suppliers in a timely manner; costs of future activities; capital and operating expenditures; success of exploration activities; mining or processing issues; exchange rates; and all of the factors and assumptions described in the management discussion and analysis of the Company and the technical reports on the Company’s projects, all of which are available under the profile of the Company on SEDAR at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements, except in accordance with applicable securities laws.

Gross Revenue of US$165.72 Million and Cash Cost of US$1,243/Oz

VANCOUVER, British Columbia, Sept. 30, 2026 (GLOBE NEWSWIRE) — Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) “Monument” or the “Company” today announced its annual financial results for the year ended June 30, 2026 (“Fiscal 2026” or “FY 2026”). All amounts are in United States dollars unless otherwise indicated (refer to www.sedar.com for full financial results).

Fiscal 2026 gold production generated gross revenue of $165.72 million, compared to $98.64 million. Net earnings of $68.80 million, or $0.20 per share, up from $37.54 million, or $0.11 per share, in the prior year. The Company’s financial position has improved, with cash flow rising to $82.21 million from $48.65 million last year, cash reserves increasing to $109.56 million from $45.94 million and working capital strengthening to $122.86 million from $58.54 million.

Cathy Zhai, the President and CEO commented: “Fiscal 2026 strengthened Monument’s financial foundation while Selinsing continued to generate substantial cash flow. Our priorities are clear: sustain Selinsing production, accelerate exploration to extend mine life, advance Murchison toward a potential second source of cash flow, and deploy capital selectively toward growth and shareholder value.”

Fiscal Year 2026 Highlights:

  • The earnings per share reached $0.20 per share (FY2025: $0.11/share);
  • Net profit of $68.80 million (FY 2025: $37.54 million);
  • Gross margin of $109.76 million for FY 2026, a 69% increase compared to $65.11 million in FY 2025;
  • $109.56 million of Cash and Cash Equivalent and short investment comprised Cash & Cash Equivalent of $37.10 million (FY2025: $45.90 million) and $72.46 million of term deposit (FY2025: nil) invested over 90 to 270 days.
  • Working capital of $122.86 million, an increase of $64.32 million from $58.54 million at the end of June 30, 2025;
  • Production performance:
    • 44,942 ounces of gold produced during the year (FY 2025: 38,530 ounces);
    • 45,010 ounces of gold sold at an average realized price of $4,280/oz for a gross revenue of $165.72 million (FY 2025: 41,183 ounces sold at an average realized price of $2,947/oz for gross revenue of $98.64 million);
    • Cash cost of $1,243 per ounce sold (FY 2025: $814/oz), reflecting higher mining cost as mining went deeper, increased royalty rates and higher royalty payment per ounce corresponding to higher gold price; partially offset by increased gold recovery rates;
    • All in sustaining cost of $1,446 per ounce sold for FY 2026, compared to $1,093/oz in FY 2025.
  • Extensive exploration drilling activities were carried out at Selinsing during FY 2026 targeting potential resource growth and future mine life extension opportunities;
  • A one-time Special Dividend of $5.04 million (CAD$6.91 million) paid to shareholders on January 19, 2026, reflecting the Company’s commitment to shareholder value.
  • On February 18, 2026, the Company was recognized as one of the top-performing companies on the TSX Venture Exchange (“TSXV”) for 2025, earning a place on the 2026 TSX Venture 50™ list.

Fourth Quarter Operation Highlights:

  • During Q4 FY2026, the Selinsing Gold Mine produced 9,902 ounces of gold, with sales of 9,581 ounces gold in concentrate yielding gross revenue of $37.05 million, at a realized gold price per ounce of $4,349 (London PM average gold price: $4,506/oz), compared to gross revenue of $39.63 million from 14,527 ounces sold at a realized gold price per ounce of $3,368 (London PM average gold price: $3,280/oz) for the three months ended June 30, 2025;
  • Cash cost per ounce for gold concentrate sold at $1,433/oz (Q4 FY2025: $701/oz), reflecting higher mining cost as mining went deeper, higher royalty per ounce of gold sold due to higher royalty rate and higher gold price;
  • AISC increased to $1,898/oz (Q4 FY2025: $853/oz).

Fourth Quarter and Fiscal Year 2026 Production and Financial Highlights 

  Three months ended June 30, Year ended June 30,  
  2026 2025   2026 2025
Production        
Ore mined (tonnes) 222,835 193,481   868,712 726,012
Waste removed (tonnes) 1,839,377 2,138,118   7,841,692 8,592,126
Gold Sulphide Production        
Ore processed (tonnes) 234,007 235,264   941,525 786,241
Average mill feed grade (g/t) 1.48 1.82   1.66 1.79
Processing recovery rate (%) 88.77 89.50   89.49 85.32
Gold produced (oz) 9,902 12,315   44,942 38,530
Gold sold (oz) 9,581 14,527   45,010 41,183
         
Financial (expressed in thousands of US$) $ $ $ $
Revenue 37,046 39,625   165,715 98,639
Gross margin from mining operations 23,307 29,449   109,759 65,112
Net Income before other items 18,446 24,754   88,128 51,075
Net Income 15,489 20,837   68,795 37,536
Cash flows provided by operations 13,855 18,932   82,208 48,652
Working capital 122,858 58,544   122,858 58,544
         
Earnings per share – basic and diluted (US$/share) 0.04 0.06   0.20 0.11
         
Weighted average gold price US$/oz US$/oz US$/oz US$/oz
Realized price – sulphide production 4,349 3,368   4,280 2,947
         
Cash cost per ounce sold        
Mining 387 241   343 239
Processing 341 262   291 285
Royalties 575 97   500 192
Rehabilitation fund levy 39 26   37 24
Operations 91 75   72 74
Total cash cost per ounce sold(1) 1433 701   1243 814
Operation expenses 2 1   1 3
Corporate expenses 28 (3 ) 8 10
Accretion of asset retirement obligation 6 4   5 6
Exploration and evaluation expenditures 44 25   11 15
Sustaining capital expenditures 385 125   178 245
Total all-in sustaining costs per ounce sold(2) 1,898 853   1,446 1,093

(1)  Total cash cost for sulphide plant production includes production costs such as mining, processing, tailing facility maintenance and camp administration, royalties, rehabilitation fund levy, and operating costs such as storage, temporary mine production closure, community development cost and property fees. Cash costs exclude amortization, depletion, accretion expenses, operation expenses, capital costs, exploration costs and corporate administration costs.
(2)  All-in sustaining cost per ounce includes total cash costs, operation expenses, and adds sustaining capital expenditures, corporate administrative expenses for the Selinsing Gold Mine including share-based compensation, exploration and evaluation costs, and accretion of asset retirement obligations. Certain other cash expenditures, including tax payments and acquisition costs, are not included.

GOLD PRODUCTION RESULTS

Annual gold production

  • During the year ended June 30, 2026, 44,942 ounces of gold, after the adjustment of 2,536 ounces of gold production, resulting from the processing of 941,525 tonnes of ore at an average feed grade of 1.66 g/t. During the year ended June 30, 2025, 38,530 ounces of gold were produced from 786,241 tonnes of ore processed through the flotation plant at an average feed grade of 1.79 g/t and a recovery rate at 85.32%.
  • Mining activities continued to focus on Buffalo Reef and Felda Block 7, supplying ore to the Selinsing sulphide plant during the year ended June 30, 2026. A total of 868,712 tonnes of ore was mined (FY 2025: 726,012 tonnes) and 7,841,692 tonnes of waste (FY 2025: 8,592,126 tonnes) moved at a lower stripping ratio of 9.03 compared to 11.83 in the prior year primarily as the main orebody of sulphide ores was reached.

Fourth quarter gold production

Gold produced from the sulphide flotation plant was 9,902 ounces, including an additional 603 ounces adjustment, in Q4 FY 2026, resulting from the processing of 234,007 tonnes of ore at a feed grade of 1.48 g/t gold and a recovery rate of 88.77%. (Q4 FY 2025: 12,315 ounces).

FINANCIAL RESULTS

Fiscal 2026 financial results

  • During the year ended June 30, 2026, revenue from sulphide gold production was $165.72 million (FY 2025: $98.64 million), as a result of the sale of 45,010 ounces of gold concentrate at a realized gold price of $4.280 per ounce (FY 2025: 41,183 ounces at $2,947/oz).
  • The gross margin was higher at $109.76 million (FY 2025: $65.11 million) due to increased gold concentrate sales at higher realized gold prices.
  • The cash cost for sulphide flotation gold concentrate production was $1,243 per ounce for FY 2026 (FY 2025: $814 per ounce for gold concentrate), led by higher mining costs, an increased royalty rate and higher royalty costs per ounce associated with stronger realized gold prices, and lower feed grades, partially offset by improved recovery rates.
  • As of June 30, 2026, cash reserves totaled $109.56 million, comprising cash and cash equivalents of $37.10 million and short-term investment – term deposits of $72.46 million, an increase of $63.62 million from cash and cash equivalents of $45.94 million as of June 30, 2025.
  • Cash used in investing activities of $85.93 million (FY 2025: $13.54 million) represented $72.46 million in short-term investments (FY 2025: nil), $11.61 million invested in Selinsing mainly for cutback and stripping activities, expansion drilling and geological work, Flotation Plant improvements, and Tailings Storage Facility (“TSF”) upgrades (FY 2025: $12.29 million), and $1.86 million (FY 2025: $1.25 million) invested in Murchison exploration and evaluation projects.

Quarter four financial results

  • Q4 FY 2026 revenue from gold concentrate production was $37.05 million, derived from the sale of 9,581 ounces of gold at an average realized price of $4,349 per ounce (Q4 FY 2025:39.63 million from 14,527 ounces of gold at $3,368/oz).
  • Mining operations before non-cash amortization and depreciation generated a gross margin of $23.31 million, decrease from $29.45 million in Q4 FY2025 and resulting from less gold concentrate sales, offset by a higher realized gold price. After accounting for operating expenses, non-cash depreciation and accretion expenses totaling $3.86 million (Q4 FY 2025: $4.36 million), the income from mining operations was $19.45 million (Q4 FY 2025: $25.09 million).
  • Total production costs during Q4 FY2026 were $13.74 million compared to $10.18 million during Q4 FY2025. The increase was due to higher royalties from royalty rate and gold price increase and higher rehabilitation fund levy from more revenue.
  • The cash cost per gold ounce sold from the sulphide operations was $1,433 for Q4 FY2026 (Q4 FY2025: $701 for sulphide operations). The increases were primarily attributable to higher royalty and rehabilitation fund levy associated with significantly stronger realized gold prices during the quarter, as well as higher mining costs driven by increased ore mined and deeper pits and additional Sales and Service Tax (“SST”) implemented by the government on mining-related services, higher milling costs from more transition ore processed, and the payment of annual bonuses.

MINE DEVELOPMENT

Selinsing Gold Mine

During FY 2026, development at Selinsing encompassed cutbacks and pre-stripping activities, drilling and geological work, tailings storage facility updates, gold concentrate warehouse expansion and flotation plant improvements. Bench scale test work was conducted for improved gold and antimony recovery. Construction of the warehouse extension was completed and extended the capacity to 7,000 Wet Metric Tonne (“WMT”) from 4,000 WMT. The TSF interim elevation of 543 mRL will provide an additional capacity of around 1.5 million tonnes, equivalent to 20 months of tailings discharge. The Computerized Maintenance Management System was successfully implemented and will contribute positively to operational efficiency, cost control, and overall asset performance.

Murchison Gold Project

At the Murchison Project, the Company continued technical and development studies, including a review of Process Design Criteria assessments including new plant options and a Statement of Work for future processing expansion opportunities, for ongoing project evaluation and development planning. Technical and economic studies continued to advance in support of a potential production restart. Other project advance activities include regulatory compliance and environmental surveys.

Exploration

Malaysia

The Buffalo Reef exploration drilling program progressed during the fourth quarter of FY 2026 with 43 holes completed and 5,868.60 metres drilled. The drilling program targeted potential extensions of mineralization outside of the current pit-shell, which may support an extension of the mine life, subject to further studies. By the end of the fourth quarter of FY 2026, a total of 18,913.10 metres had been drilled as part of the resource expansion program, and a total of 15,158 samples were prepared and dispatched to the assay laboratory.

Western Australia

No field exploration was undertaken at the Murchison Project during Q4 2026. The Company reviewed the historic resources at the Gabanintha Gold Project, including analysis of historical data. A desktop assessment identified step-out drilling targets with potential to expand the currently known mineralization, which remains open along strike. Confirmation drilling is planned to commence when regulatory compliance is met.

_______________________________________

About Monument

Monument Mining Limited (TSX-V: MMY, FSE: D7Q1) is an established Canadian gold producer that 100% owns and operates the Selinsing Gold Mine in Malaysia and the Murchison Gold Project in the Murchison area of Western Australia. It has 20% interest in Tuckanarra Gold Project, jointly owned by Odyssey Gold Ltd in the same region. The Company employs approximately 295 people in both regions and is committed to the highest standards of environmental management, social responsibility, including health and safety for its employees and neighboring communities and good corporate governance.

Cathy Zhai, President and CEO
Monument Mining Limited
Suite 1580 -1100 Melville Street
Vancouver, BC V6E 4A6

FOR FURTHER INFORMATION visit the company web site at www.monumentmining.com or contact:

Richard Cushing, MMY Vancouver         T: +1-604-638-1661 x102         rcushing@monumentmining.com

“Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”

Disclaimer Regarding Forward-Looking Statements

This news release includes statements containing forward-looking information about Monument, its business and future plans (“forward-looking statements”). Forward-looking statements are statements that involve expectations, plans, objectives or future events that are not historical facts and include the Company’s plans with respect to its mineral projects, expectations regarding the Company’s continuing ability to source explosives from suppliers and the timing and results of the other proposed programs and events referred to in this news release. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. The forward-looking statements in this news release are subject to various risks, uncertainties and other factors that could cause actual results or achievements to differ materially from those expressed or implied by the forward-looking statements. These risks and certain other factors include, without limitation: risks related to general business, economic, competitive, geopolitical and social uncertainties; uncertainties regarding the results of current exploration activities; uncertainties in the progress and timing of development activities, uncertainties and risks related to the Company’s ability to source explosives from suppliers; foreign operations risks; other risks inherent in the mining industry and other risks described in the management discussion and analysis of the Company and the technical reports on the Company’s projects, all of which are available under the profile of the Company on SEDAR at www.sedar.com. Material factors and assumptions used to develop forward-looking statements in this news release include: expectations regarding the estimated cash cost per ounce of gold production and the estimated cash flows which may be generated from the operations, general economic factors and other factors that may be beyond the control of Monument; assumptions and expectations regarding the results of exploration on the Company’s projects; assumptions regarding the future price of gold of other minerals; the timing and amount of estimated future production; assumptions regarding the timing and results of development activities; expectations that the Company will continue to be able to source explosives from suppliers in a timely manner; costs of future activities; capital and operating expenditures; success of exploration activities; mining or processing issues; exchange rates; and all of the factors and assumptions described in the management discussion and analysis of the Company and the technical reports on the Company’s projects, all of which are available under the profile of the Company on SEDAR at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements, except in accordance with applicable securities laws.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.